Oncorus repays $20M loan with K2 HealthVentures, terminates Loan Agreement; appoints interim CFO

Oncorus, Inc.

Repaid $20M principal plus ~$1.6M accrued interest and fees on May 12, 2023; Loan Agreement terminated.
Alexander Nolte appointed as principal financial officer and accounting officer, serving as interim CFO at $400/hour.
Mr. Nolte previously VP, Chief Accounting Officer at Syndax Pharmaceuticals; no family relationships disclosed.

item 1.02 item 2.04 item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed (interim)

Alexander Nolte

interim Chief Financial Officer

Oncorus, Inc.

Effective: 2023-05-18
Filed: May 18, 2023, 7:59 PM ET

On May 18, 2023, the Company's board of directors appointed Alexander Nolte as the Company’s principal financial officer and principal accounting officer. Mr. Nolte will serve as the Company’s interim Chief Financial Officer pursuant to a consulting arrangement described below.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Alexander Nolte was appointed as interim Chief Financial Officer at Oncorus, Inc..

Action: appointed
Role: interim Chief Financial Officer

Exact text from the filing

On May 18, 2023, the Company's board of directors appointed Alexander Nolte as the Company’s principal financial officer and principal accounting officer. Mr. Nolte will serve as the Company’s interim Chief Financial Officer pursuant to a consulting arrangement described below.

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

Oncorus, Inc. terminated Loan and Security Agreement with K2 HealthVentures LLC valued at paid in full all outstanding obligations: $20.0 million principal and approximately $1.6 million acc (effective 2023-05-12).

Action: termination
Agreement: credit facility
Counterparty: K2 HealthVentures LLC
Value: paid in full all outstanding obligations: $20.0 million principal and approximately $1.6 million acc
Effective: 2023-05-12

Exact text from the filing

On May 12, 2023, the Company paid in full all of its outstanding obligations and other fees due under the Loan Agreement, consisting of $20.0 million in principal and approximately $1.6 million of accrued interest and related fees and expenses.

View on SEC.gov

44 material agreements filed in the last 30 days. Browse all material agreements →

Source: SEC EDGAR

accession 0000950170-23-023023

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.